
AAPG
Healthcare · Biotechnology · $1.37B market cap
$14.62-0.40 (-2.7%)Nov 13, 4:00 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -16.8% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 1, 2026 | Time not confirmed | -0.58 | 0.00 | +100.0% |
| Dec 3, 2025 | Time not confirmed | -0.42 | -0.42 | 0.0% |
| Aug 7, 2025 | Time not confirmed | 0.00 | -1.73 | — |
| Apr 16, 2025 | Time not confirmed | — | -1.82 | — |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic…